VSGN is dripping south slowly, but I am confident this stock will bounce back up above 2 in the near future. I just don't see VSGN announces any bad news at this conference, if anything at all, it should be positive. I will continue to accumulate this stock until June 14, pending the outcome of the conference presentation.
***************************************************************
VSGN Present at Needham & Company Biotechnology and Medical Technology Conference
MISSISSAUGA, ON, June 7 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference at the New York Palace Hotel at 11:00 a.m. Eastern Time on Wednesday, June 14, 2006 in New York City.
A live audio web cast of the presentation can be accessed through Vasogen's Web site at: www.vasogen.com. An archived replay will be available following the presentation.
About Vasogen:
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company is currently in the final stages of completing the international pivotal phase III ACCLAIM trial in 2,400 patients with advanced chronic heart failure. The ACCLAIM trial is a 176-center study designed to further investigate the use of Vasogen's Celacade(TM) technology to reduce the risk of death and hospitalization in heart failure patients and support regulatory approval in North America and commercialization in North America and Europe. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs. |
